Celularity Inc (CELU)vsRegeneron Pharmaceuticals Inc (REGN)
CELU
Celularity Inc
$1.21
-4.72%
HEALTHCARE · Cap: $35.18M
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 35246% more annual revenue ($14.34B vs $40.58M). REGN leads profitability with a 31.4% profit margin vs -2.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
CELU
Avoid19
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CELU.
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Smaller company, higher risk/reward
ROE of -63.7% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CELU profiles as a turnaround stock while REGN is a value play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.79 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 19/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a leading biotechnology firm focused on transforming the landscape of regenerative medicine through its unique therapeutic cellular products derived from the placenta. With a strong pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, the company aims to enhance treatment efficacy while reducing associated complications for cancer and other serious illnesses. Driven by an experienced leadership team and strategic partnerships, Celularity is well-positioned to address significant unmet medical needs, solidifying its role as a key player in the rapidly evolving field of advanced therapeutics.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?